The Comparative Study on the Application Value of Transperineal Prostate Combined Biopsy and Transrectal Prostate Systematic Biopsy in Diagnosing Prostate Cancer in Patients with Different PSA Zones
Urology Journal,
Vol. 22 No. 01 (2025),
12 January 2025
,
Page 37-43
https://doi.org/10.22037/uj.v21i.8275
Abstract
Purpose: This study aimed to compare the effects of transperineal prostate combined biopsy (TP-CB) and transrectal prostate systematic biopsy (TR-SB) on the detection rate and safety of prostate cancer in patients with prostate-specific antigen (PSA) gray zone, PSA levels of 10~20 ng/mL, and 20~40 ng/mL, and explore the comparative value of their applications.
Materials and Methods: We collected 243 samples from patients with PSA ≤ 40 ng/mL who underwent prostate biopsy. All patients were divided into two groups according to different patterns of prostate biopsy. The detection rates of prostate cancer and clinically significant prostate cancer (CsPCa) in patients with PSA levels of 4~10,10~20, and 20~40 ng/mL were compared between two different biopsy methods, surgical conditions, and the incidence of complications.
Results: The rate of a positive prostate cancer biopsy was significantly higher in TP-CB than in TR-SB (P < 0.05). Further subgroup analyses revealed no statistical significance in the rate of positive prostate cancer biopsy in patients with PSA levels of 4~10 and 20~40 ng/mL between the two groups (P > 0.05). However, patients with PSA levels of 10~20 ng/mL in the TP-CB group exhibited a higher detection rate (P < 0.05), with CsPCa accounting for a higher proportion. The TP-CB and TR-SB groups did not exhibit a significant difference in surgical conditions or overall complication rates (P > 0.05). However, the TR-SB group exhibited a higher risk of postoperative febrile infection than the TP-CB group (P < 0.05).
Conclusion: For patients with PSA in the 'sub-gray zone' (10~20 ng/mL), TP-CB has a better diagnostic and application value and is more suitable for clinical promotion.
- transperineal prostate combined biopsy
- transrectal prostate systematic biopsy
- PSA sub-gray zone
- clinically significant prostate cancer
- detection rate
How to Cite
References
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca-cancer j clin. 2024;74:12-49.
Ye C, Ho JN, Kim DH, Song SH, Kim H, Lee H, et al. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations. Investig clin urol. 2022;63:631-8.
Milkovic B, Dzamic Z, Pejcic T, Kajmakovic B, Nikolic D, Cirovic D, et al. Evaluation of free-to-total prostate specific antigen (F/T PSA), prostate specific antigen density (PSAD) and (F/T)/PSAD sensitivity on reduction of unnecessary prostate biopsies for patients with PSA in gray zone. Ann ital chir. 2014;85:448-53.
Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. Eur urol. 2019;76:43-51.
Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T, Gholamrezanezhad A. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Rev esp med nucl ima. 2013;32:286-9.
Chong A, Hwang I, Ha JM, Yu SH, Hwang EC, Yu HS, et al. Application of bone scans for prostate cancer staging: Which guideline shows better result? Cuaj-can urol assoc. 2014;8:E515-9.
Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J natl compr canc ne. 2010;8:240-62.
Zaman MU, Fatima N, Sajjad Z. Metastasis on bone scan with low prostate specific antigen (≤20 ng/ml) and Gleason's score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines? Asian pac j cancer p. 2011;12:1529-32.
Carter HB, Landis PK, Epstein JI, Walsh PC. Expectant management of prostate cancer with curative intent. Eur urol. 2001;39 Suppl 4:24.
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur urol. 2013;64:876-92.
Elwenspoek MMC, Sheppard AL, McInnes MDF, Merriel SWD, Rowe EWJ, Bryant RJ, et al. Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2:e198427.
Tonttila PP, Lantto J, Pääkkö E, Piippo U, Kauppila S, Lammentausta E, et al. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial. Eur urol. 2016;69:419-25.
Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New engl j med. 2020;382:917-28.
Filella X, Foj L. Novel Biomarkers for Prostate Cancer Detection and Prognosis. Adv exp med biol. 2018;1095:15-39.
Filella X, Foj L. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int J Mol Sci. 2016;17:null.
Lee J, Yang SW, Jin L, Lee CL, Lee JY, Shin JH, et al. Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels? BMC Cancer. 2021;21:472.
Lee SH, Chung MS, Park KK, Yom CD, Lee DH, Chung BH. Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL? World j urol. 2012;30:265-9.
Sanjaya IP, Mochtar CA, Umbas R. Correlation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans? Asian pac j cancer p. 2013;14:4973-6.
Wong LM, Sutherland T, Perry E, Tran V, Spelman T, Corcoran N, et al. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). Eur Urol Oncol. 2024;null.
Jiang W, Gao Y, Wen M, Ye Z, Liang H, Wu D, et al. Preliminary evaluation for ultrasound-guided targeted prostate biopsy using a portable surgical robot: Ex vivo results. Int j med robot comp. 2023;e2597.
Kubo Y, Kawakami S, Numao N, Takazawa R, Fujii Y, Masuda H, et al. Simple and effective local anesthesia for transperineal extended prostate biopsy: application to three-dimensional 26-core biopsy. Int j urol. 2009;16:420-3.
Guo LH, Wu R, Xu HX, Xu JM, Wu J, Wang S, et al. Comparison between Ultrasound Guided Transperineal and Transrectal Prostate Biopsy: A Prospective, Randomized, and Controlled Trial. Sci Rep. 2015;5:16089.
He J, Guo Z, Huang Y, Wang Z, Huang L, Li B, et al. Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis. Urol oncol-semin ori. 2022;40:191.e9-.e14.
Pepe P, Aragona F. Prostate biopsy: results and advantages of the transperineal approach--twenty-year experience of a single center. World j urol. 2014;32:373-7.
Chang DT, Challacombe B, Lawrentschuk N. Transperineal biopsy of the prostate--is this the future? Nat rev urol. 2013;10:690-702.
- Abstract Viewed: 531 times
- 8275/pdf Downloaded: 330 times